Glioblastoma multiforme: the aggressive void in cancer care

Imagine a young father of two in the suburbs of Pakistan, diagnosed with glioblastoma multiforme (GBM). He has exhausted all treatment options available locally and has gone bankrupt now. With no access to advanced neuro-oncology, his family turns to alternative medicine, clinging to hope in the face of failing healthcare. GBM, the most aggressive and common form of primary brain malignancy, represents not only a formidable clinical entity but also a stark reflection of global inequities in cancer care delivery1. Despite therapeutic advancements, the prognosis for GBM remains grim. A landmark study demonstrated a median survival of 14.6 months in patients treated with radiotherapy and temozolomide, compared to 12.1 months in those receiving radiotherapy alone. The 2-year survival rate improved from 10.4% to 26.5% with the addition of temozolomide, albeit with grade 3 or 4 hematologic toxicity in 7% of patients2. Overall, the average survival post-diagnosis hovers around 15 months, with GBM exhibiting a higher incidence in men. Malignant gliomas account for approximately 2.5% of all cancer-related deaths worldwide3. Standard-of-care management includes maximal safe surgical resection followed by adjuvant radiotherapy and chemotherapy. Nevertheless, survival outcomes have shown little improvement over recent decades3. A recent cohort study revealed that the majority of GBM patients were from middle- (39.6%) or lower-income (42.7%) backgrounds, with 63.8% receiving treatment in public sector hospitals. Gross total resection was achieved in 47.3% of cases, with multiple reoperations performed for tumor recurrence. At the conclusion of follow-up, only 33% of patients were documented as alive, while nearly 47% were lost to follow-up – underscoring a critical gap in long-term care continuity4. While significant strides have been made in the fields of neuro-oncology and neurosurgery, these advances have not translated equally across all regions. Low- and middle-income countries (LMICs) remain disproportionately affected by systemic barriers in cancer diagnosis and treatment5. Limited case ascertainment, driven by weak surveillance infrastructure, results in underestimation of disease burden and delayed tumor presentation, both of which contribute to poorer clinical outcomes. Additionally, the financial burden of GBM treatment is profound. In many LMICs, access to radiation therapy and chemotherapeutic agents such as temozolomide is either cost-prohibitive or entirely lacking. Compounding these challenges is a shortage of trained neurosurgeons, under-resourced operating rooms, inadequate laboratory support, and limited access to advanced imaging technologies – all of which significantly hinder timely and effective care5. Addressing these systemic deficiencies is essential to improving outcomes for GBM patients in resource-limited settings. Current therapeutic regimens remain centered on surgery, radiotherapy, and chemotherapy. While agents like bevacizumab have been introduced for recurrent disease, survival gains have been marginal. Despite intensive research into novel treatment modalities – including immunotherapies, small-molecule inhibitors, natural compounds, and glioblastoma stem cell-targeted therapies – progress has been incremental at best6. Moreover, end-of-life care for GBM patients, particularly in LMICs, remains insufficiently addressed. These patients frequently endure debilitating neurological symptoms such as seizures, incontinence, and cognitive decline, alongside systemic complications like infections and thromboembolic events. The incorporation of comprehensive palliative care services is vital to alleviating suffering and supporting both patients and their families through the final stages of illness7–10. GBM remains a formidable malignancy with limited therapeutic gains and a persistently poor prognosis. In LMICs, systemic barriers further exacerbate outcomes, revealing deep inequities in cancer care. Addressing these challenges through equitable access to treatment, strengthened healthcare infrastructure, and integrated palliative services is essential11–14. While a cure may remain elusive, mitigating GBM’s burden is both a clinical priority and a moral obligation.